Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J de Bono

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumoursA Suder, J E Ang, F Kyle, et al.
British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000D J Propper, J de Bono, A Saleem, et al.
British Journal of Cancer|December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysC Benson, J White, J De Bono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer|August 27, 2009
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangementC S Foster, A R Dodson, L Ambroisine, et al.
Oncogene|October 9, 2007
Complex patterns of ETS gene alteration arise during cancer development in the human prostateJ Clark, G Attard, S Jhavar, et al.
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumoursA Suder, J E Ang, F Kyle, et al.
British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000D J Propper, J de Bono, A Saleem, et al.
British Journal of Cancer|December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysC Benson, J White, J De Bono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer|August 27, 2009
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangementC S Foster, A R Dodson, L Ambroisine, et al.
Oncogene|October 9, 2007
Complex patterns of ETS gene alteration arise during cancer development in the human prostateJ Clark, G Attard, S Jhavar, et al.
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Pageof 5